Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Biochemical Engineering >Inhibitors >GPCR & G Protein >Vasopressin Receptor Antagonists >Tolvaptan

Tolvaptan

Tolvaptan Structure
  • ₹12178.13 - ₹51462.05
  • Product name: Tolvaptan
  • CAS: 150683-30-0
  • MF: C26H25ClN2O3
  • MW: 448.94
  • EINECS:691-537-5
  • MDL Number:MFCD09838782
  • Synonyms:N-[4-(9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide;Tolvaptan;N-[4-[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]-3-methylphenyl]-2-methylbenzamide;N-(4-{[(5R)-7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-Methylphenyl)-2-MethylbenzaMide;OPC 41061;OPC-41061;SaMsca;Tolvaptan Tablets
2 prices
Selected condition:

Brand

  • Sigma-Aldrich(India)

Package

  • 5MG
  • 25MG
  • ManufacturerSigma-Aldrich(India)
  • Product numberT7455
  • Product descriptionTolvaptan ≥98% (HPLC), powder
  • Packaging5MG
  • Price₹12178.13
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberT7455
  • Product descriptionTolvaptan ≥98% (HPLC), powder
  • Packaging25MG
  • Price₹51462.05
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
Sigma-Aldrich(India) T7455 Tolvaptan ≥98% (HPLC), powder 5MG ₹12178.13 2022-06-14 Buy
Sigma-Aldrich(India) T7455 Tolvaptan ≥98% (HPLC), powder 25MG ₹51462.05 2022-06-14 Buy

Properties

Melting point :219-222°C
Boiling point :594.4±50.0 °C(Predicted)
Density :1.311±0.06 g/cm3(Predicted)
storage temp. :2-8°C
solubility :DMSO: ≥15mg/mL
form :powder
pka :13.00±0.70(Predicted)
color :white to tan
InChIKey :GYHCTFXIZSNGJT-UHFFFAOYSA-N
SMILES :C(NC1=CC=C(C(N2C3=CC=C(Cl)C=C3C(O)CCC2)=O)C(C)=C1)(=O)C1=CC=CC=C1C

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H361 Suspected of damaging fertility or the unborn child Reproductive toxicity Category 2 Warning P201, P202, P281, P308+P313, P405,P501
H362 May cause harm to breast-fed children Reproductive toxicity, effects on or via lactation Additional category P201, P260, P263, P264, P270,P308+P313
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P263 Avoid contact during pregnancy/while nursing.
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P281 Use personal protective equipment as required.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P405 Store locked up.
P501 Dispose of contents/container to..…

Description

Tolvaptan(trade names Samsca and Jinarc) is an oral selective vasopressin antagonist developed by Otsuka for the treatment of hyponatremia, and it is a non-peptide selective antidiuretic hormone receptor antagonist. The drug can increase the concentration of sodium ions in the plasma, and help the excess water discharge from the urine. The drug could enhance the ability of the kidney to deal with water, and significantly reduce the weight and edema of patients while not accompanied by increased electrolyte excretion, without destroying the blood electrolyte balance. The drug can be used to treat hyponatremia caused by congestive heart failure, various edematous diseases, cirrhosis and antidiuretic hormone deficiency syndrome. The study found that, when the plasma sodium concentration decreased, in order to maintain the balance of sodium concentration inside and outside the cell, extracellular fluid will enter the cell, so the cells will swell. When the brain cells swell, it will lead to a variety of hyponatremia symptoms, including dizziness, weakness, headache, nausea, confusion, consciousness and convulsions. Severe hyponatremia can lead to coma and death. There is no corresponding study of tolvaptan tablets in patients with severe hyponatremia.

Related product price